Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2016-07-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金临时性补充流动资金归还的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the temporary use of idle raised funds to supplement working capital and the subsequent full repayment of those funds. It includes details about board and supervisory meetings approving the use of funds, the amount, duration, and repayment date. The document is short (757 characters) and serves as an update on capital usage and repayment rather than a detailed financial report or audit. It fits the description of a Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management.
2016-07-29 Chinese
关于实施2015年度权益分派方案后调整非公开发行股票发行价格的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shandong Ruikang Pharmaceutical Co., Ltd. regarding the adjustment of the issuance price for a non-public stock offering following the implementation of the 2015 profit distribution plan. It details the price adjustment formula, references shareholder meetings approving the plan, and confirms the completion of the 2015 profit distribution. The document is short (1529 characters) and focuses on changes to the capital raising terms rather than presenting financial statements or comprehensive financial data. It is not an annual or interim report, nor an earnings release. It is clearly an update on financing activity related to share issuance. Therefore, the document fits the category of Capital/Financing Update (CAP).
2016-07-13 Chinese
关于非公开发行股票申请获得中国证监会核准批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding the approval from the China Securities Regulatory Commission (CSRC) for a non-public issuance of shares. It includes details about the approval, the number of shares to be issued, validity period, and contact information. The document is short (843 characters) and serves as an official notice of a capital raising event rather than a detailed financial report or presentation. It does not contain financial statements or detailed analysis but rather an update on financing activity. Therefore, it fits the category of Capital/Financing Update (CAP).
2016-07-13 Chinese
第二届董事会第三十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Shandong Ruikang Pharmaceutical Co., Ltd. It details the approval of various credit and loan applications and authorizations for the company president to handle related contracts. The document includes voting results and references to the board meeting but does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is not a call transcript or investor presentation. The document is a formal announcement of board decisions, specifically about financing approvals, but it is not a direct financing update or capital change announcement. Given the nature of the content—board meeting resolutions and decisions—it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or presentation. Therefore, the classification is MANG with high confidence.
2016-07-06 Chinese
关于实际控制人进行股票质押式回购交易的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the stock pledge and repurchase transactions by the actual controller of the company, including details about pledged shares, dates, and percentages. It does not contain financial statements, earnings data, or management discussion. It is a regulatory announcement about share pledging activity by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or earnings release.
2016-06-24 Chinese
关于深圳证券交易所2015年年度报告问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed response from Shandong Ruikang Pharmaceutical Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2015 annual report. It addresses specific questions about financial figures, cash flow, credit policies, acquisition funding, goodwill impairment testing, and related party transactions. The content is focused on clarifying and explaining points raised about the annual report rather than presenting the annual report itself. The document length is 6449 characters, which is substantial but the nature of the document is a reply to an inquiry letter, not the full annual report. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory response to a stock exchange inquiry about the annual report, not the annual report itself or an announcement of its publication.
2016-06-06 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.